Published On: Jul 25, 2025
Last Updated On: Jul 25, 2025
Today the eczema community is one step closer to having a new treatment option. The U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, from manufacturer LEO Pharma Inc., as the first topical treatment of moderate-to-severe chronic hand eczema (CHE) in adult patients whose disease is not adequately controlled with topical corticosteroids, or when those therapies are not advisable. ANZUPGO is a JAK (Janus kinase) inhibitor cream and will be available by prescription only.
CHE is an inflammatory skin condition characterized by redness, itchiness, dryness or burning on the skin of the hands or wrists. CHE is a condition that lasts for more than three months or recurs two or more times a year, causing significant discomfort. ANZUPGO works by blocking specific JAK proteins that act like switches in your immune system, contributing to inflammation.
It’s important to talk to your doctor about how chronic hand eczema affects your skin and other aspects of your life. Together, you and your healthcare provider can determine if ANZUPGO is an appropriate treatment option.
To learn more about ANZUPGO, read the Prescribing Information and Medication Guide.
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet…
Learn what’s new and exciting in eczema research from the National Eczema Association research team.
Dermatologists weigh in on the benefits of LED face masks for eczema.
Learn why eczema often changes during puberty, common triggers for teens and how to minimize flares and find relief.
Evidence-based articles, expert-sourced lifestyle tips and stories from your community.